Bempedoic Acid in Patients with High Uric Acid Levels
Bempedoic acid can be used in patients with hyperuricemia, but requires baseline uric acid assessment and ongoing monitoring, with readiness to initiate urate-lowering therapy if symptomatic hyperuricemia or gout develops. 1, 2
Key Mechanism and Risk
Bempedoic acid inhibits renal tubular organic anion transporters (OAT2 and OAT3), which directly impairs uric acid excretion and predictably raises serum uric acid levels 2. This is a known, mechanism-based adverse effect rather than an idiosyncratic reaction.
Clinical Significance of Hyperuricemia with Bempedoic Acid
Incidence Data from Trials
- Primary hyperlipidemia trials: 26% of bempedoic acid-treated patients with normal baseline uric acid developed hyperuricemia (vs. 9.5% placebo), with mean increase of 0.8 mg/dL after 12 weeks 2
- Cardiovascular outcomes trial: 16.4% experienced clinically significant hyperuricemia (vs. 8.2% placebo) 2
- Gout incidence: 3.2% in cardiovascular outcomes trial (vs. 2.2% placebo) and 1.5% in primary hyperlipidemia trials (vs. 0.4% placebo) 2
Real-World Evidence
Recent real-world data from 7,676 matched patients showed bempedoic acid increased laboratory-defined hyperuricemia (HR 1.94,95% CI 1.58-2.37) compared to ezetimibe, but this did NOT translate into increased anti-gout medication use (HR 1.06,95% CI 0.86-1.29) 3. This suggests the clinical impact may be less severe than laboratory values alone suggest.
Appropriateness in Patients with Pre-existing Hyperuricemia
Bempedoic acid is not contraindicated in patients with elevated uric acid, but requires careful consideration 1, 2:
- No absolute contraindication exists for hyperuricemia
- The drug is FDA-approved for cardiovascular risk reduction and LDL-C lowering without restrictions based on uric acid levels 2
- Guidelines emphasize monitoring rather than avoidance 1
When to Exercise Caution
Consider alternative lipid-lowering therapy if:
- History of recurrent gout flares
- Symptomatic hyperuricemia despite urate-lowering therapy
- Patient unable to tolerate or access urate-lowering medications
- Baseline uric acid >9 mg/dL with no current treatment
Required Monitoring Protocol
Baseline Assessment
Measure serum uric acid before initiating bempedoic acid 1, 2
Ongoing Monitoring
- Assess uric acid within first 4 weeks (when increases typically occur) 2
- Monitor for signs/symptoms of hyperuricemia throughout treatment 1, 2
- Uric acid elevations persist during treatment but return to baseline after discontinuation 2
Clinical Surveillance
Advise patients to report symptoms of:
- Joint pain, swelling, or warmth (gout flare)
- New onset of acute monoarticular arthritis
- Worsening of pre-existing gout 1, 2
Management Strategy for Hyperuricemia
Initiate urate-lowering drugs as appropriate when hyperuricemia develops 1, 2. The guidelines explicitly state to treat with urate-lowering therapy rather than discontinue bempedoic acid.
Practical Approach:
- If asymptomatic hyperuricemia develops: Continue bempedoic acid, monitor clinically
- If symptomatic hyperuricemia or gout occurs: Add allopurinol or febuxostat; continue bempedoic acid if cardiovascular benefit outweighs risk
- If recurrent gout despite urate-lowering therapy: Consider alternative lipid-lowering agent
Important Contextual Considerations
Cardiovascular Benefit vs. Uric Acid Risk
The cardiovascular outcomes data showed no increased incidence of hypertension or heart failure with bempedoic acid despite uric acid elevation, and cardiovascular event reduction was comparable to statins for equivalent LDL-C lowering 4. This suggests the uric acid increase does not negate cardiovascular benefits.
Other Safety Concerns
Tendon rupture risk (1.2% vs. 0.9% placebo) may be more clinically significant than hyperuricemia, particularly in patients >60 years, those on corticosteroids/fluoroquinolones, or with history of tendon disorders 1, 2. Discontinue immediately if tendon rupture occurs.
Clinical Bottom Line
Do not withhold bempedoic acid solely based on elevated uric acid levels. The drug provides meaningful cardiovascular risk reduction and LDL-C lowering 2. Instead, implement a monitoring protocol with readiness to add urate-lowering therapy. The real-world evidence suggests laboratory hyperuricemia often does not require treatment intervention 3. Baseline uric acid measurement and patient education about gout symptoms are mandatory before initiation 1, 2.